Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

Laurie H. Sehn, MD, MPH, clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, discusses bioengineered monoclonal antibodies and their promising future in treating patients with lymphoma. At the 53rd Annual Meeting of the American Society of Hematology, held in San Diego, Sehn presented phase II data on GA101, a monoclonal antibody that targets CD20, and how it might perform even better than rituximab, a practice-changing therapy for patients with non-Hodgkin lymphoma.